Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of... – Animal cell – per se – expressing immunoglobulin – antibody – or...
Reexamination Certificate
2007-08-07
2007-08-07
Spector, Lorraine (Department: 1646)
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
Animal cell, per se, expressing immunoglobulin, antibody, or...
C435S344000, C424S142100, C424S143100, C424S155100, C530S388150, C530S388220, C530S388800, C530S391300, C530S391700, C530S350000
Reexamination Certificate
active
10480730
ABSTRACT:
Human Death Receptor 4 (DR4) antibodies are provided. The human DR4 antibodies may be included in pharmaceutical compositions, articles of manufacture, or kits. Methods of treatment and diagnosis using the DR4 antibodies are also provided.
REFERENCES:
patent: 5677165 (1997-10-01), de Boer et al.
patent: 6342383 (2002-01-01), Perron et al.
patent: 6433147 (2002-08-01), Ni et al.
patent: 6461823 (2002-10-01), Ni et al.
patent: 6943020 (2005-09-01), Ni et al.
patent: 6989144 (2006-01-01), Busfield et al.
patent: 7060272 (2006-06-01), Ni et al.
patent: 2003/0036168 (2003-02-01), Ni et al.
patent: 2003/0073187 (2003-04-01), Ni et al.
patent: 2003/0108516 (2003-06-01), Ni et al.
patent: 2003/0133932 (2003-07-01), Zhou et al.
patent: 2004/0120947 (2004-06-01), Ashkenazi et al.
patent: 2004/0180049 (2004-09-01), Ashkenazi et al.
patent: 0388151 (1990-03-01), None
patent: 417563 (1991-03-01), None
patent: 870827 (1998-10-01), None
patent: WO 92/15698 (1992-09-01), None
patent: WO 97/01633 (1997-01-01), None
patent: WO 97/25428 (1997-07-01), None
patent: WO 98/18921 (1998-05-01), None
patent: WO 98/28426 (1998-07-01), None
patent: WO 98/32856 (1998-07-01), None
patent: WO 98/35986 (1998-08-01), None
patent: WO 98/39361 (1998-09-01), None
patent: WO 98/41629 (1998-09-01), None
patent: WO 98/46643 (1998-10-01), None
patent: WO 98/46751 (1998-10-01), None
patent: WO 98/51793 (1998-11-01), None
patent: WO 99/02653 (1999-01-01), None
patent: WO 99/04001 (1999-01-01), None
patent: WO 99/07738 (1999-02-01), None
patent: WO 99/09165 (1999-02-01), None
patent: WO 99/11791 (1999-03-01), None
patent: WO 99/33980 (1999-07-01), None
patent: WO 99/37684 (1999-07-01), None
patent: WO 99/64461 (1999-12-01), None
patent: WO 00/73349 (2000-12-01), None
patent: WO 02/097033 (2002-12-01), None
patent: WO 03/037913 (2003-05-01), None
patent: WO 03/038043 (2003-05-01), None
patent: WO 03/042367 (2003-05-01), None
Bodmer et al., TRAIL receptor-2 signals apoptosis through FADD and caspase-8, Nat. Cell Biol., 2:241-243, Apr. 2000.
Srivastava, R.K., TRAIL/Apo-2L: Mechanisms and Clinical Applications in Cancer, Neoplasia, vol. 3, No. 6, 2001, pp. 535-546.
Chuntharapai, et al., Isotype-Dependent Inhibition of Tumor Growth In Vivo by Monoclonal Antibodies to Death Receptor 4, Journal of Immunology, vol. 166, No. 8, Apr. 15, 2001, pp. 4891-4898.
Amakawa et al., “The Hodgkin Disease Antigen CD30 is Crucial for Antigen-Induced Death of Developing T Cells”Symposium on Programmed Cell Death(Abstract No. 10), Cold Spring Harbor Laboratory (1995).
Anderson et al., “A Homologue of the TNF Receptor and Its Ligand Enhance T-Cell Growth and Dendritic-Cell Function.”Nature. 390(6656):175-179 (Nov. 13, 1997).
Armitage et al., “Molecular and Biological Characterization of a Murine Ligand for CD40.”Nature. 357(6373):80-82 (1992).
Ashkenazi and Dixit, “Apoptosis control by death and decoy receptors”Current Opinion in Cell Biology11(2):255-269 (1999).
Ashkenazi and Dixit., “Death Receptors: Signaling and Modulation.”Science. 281(5381):1305-1308 (1998).
Ashkenazi et al., “Apoptosis regulation by death and decoy receptors”FASEB journal13:A1336 (Apr. 23, 1999).
Ashkenazi et al., “Safety and antitumor activity of recombinant soluble Apo2 ligand”Journal of Clinical Investigation104(2):155-162 (1999).
Bachmann et al., “TRANCE, A Tumor Necrosis Factor Family Member Critical for CD40 Ligand-Independent T Helper Cell Activation.”J. Experimental Medicine. 189:1025-1031 (1999).
Baldwin, A., “The NF-κB and ΥκB Proteins: New Discoveries and Insights”Ann. Rev. Immunol. 14:649-683 (1996).
Banner et al., “Crystal Structure of the Soluble Human 55 kd TNF Receptor-Human TNFβ Complex: Implications for TNF Receptor Activation”Cell73:431-445 (1993).
Bodmer et al., “Cysteine 230 Is Essential for the Structure and Activity of the Cytotoxic Ligand TRAIL”Journal of Biological Chemistry275:20632-20637 (2000).
Bodmer et al., “TRAMP, A Novel Apoptosis-Mediating Receptor with Sequence Homology to Tumor Necrosis Factor Receptor 1 and Fas(Apo-1/CD95).”Immunity. 6:79-88 (1997).
Brockhaus et al., “Identification of Two Types of Tumor Necrosis Factor Receptors on Human Cell Lines by Monoclonal Antibodies.”Proc. Natl. Acad. Sci. USA87:3127-3131 (1990).
Brojatsch et al., “CAR1, A TNFR-Related Protein, Is a Cellular Receptor for Cytopathic Avian Leukosis-Sarcoma Viruses and Mediates Apoptosis.”Cell. 87:845-855 (1996).
Browning et al., “Lymphotoxin β, a Novel Member of the TNF Family That Forms a Heteromeric Complex with Lymphotoxin on the Cell Surface”Cell72:847-856 (1993).
Chicheportiche et al., “TWEAK, A New Secreted Ligand in the Tumor Necrosis Factor Family that Weakly Induces Apoptosis.”Journal of Biological Chemistry272(51):32401-32410 (1997).
Chinnaiyan et al., “Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy”Proc. Natl. Acad. Sci. 97:1754-1759 (2000).
Chinnaiyan et al., “Signal Transduction by DR3, A Death Domain-Containing Receptor Related to TNFR-1 and CD95.”Science. 274:990-992 (1996).
Chuntharapai et al., “The induction and blocking of apoptosis by anti Apo2 monoclonal antibodies”FASEB Journal(Annual Meeting of the Professional Research Scientists for Experimental Biology) 13(4):A518 (1999).
Dealtry et al., “DNA Fragmentation and Cytotoxicity Caused by Tumor Necrosis Factor is Enhanced by Interferon-γ”European Journal of Immunology17:689-693 (1987).
Degli-Esposti et al., “Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family”Journal of Experimental Medicine186(7):1165-1170 (1997).
Degil-Esposti et al., “The Novel Receptor TRAIL-R4 Induces NF-κB and Protects against TRAIL-Mediated Apoptosis, yet Retains an Incomplete Death Domain”Immunity7:813-820 (1997).
Emery et al., “Osteoprotegerin is a Receptor for the Cytotoxic Ligand Trail.”J. Bio. Chem. 273(23):14363-14367 (1998).
Gazitt, Y., “TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and its not cytotoxic to hematopoietic stem cells”Leukemia13:1817-1824 (1999).
Gliniak and Le, “Tumor Necrosis Factor-related Apoptosis-inducing Ligand's Antitumor Activity in Vivo Is Enhanced by the Chemoptherapeutic Agent CPT-11”Cancer Research59:6153-6158 (1999).
Golstein, P., “Cell Death: TRAIL and its Receptors”Curr. Biol7:R750-R753 (1997).
Goodwin et al., “Molecular Cloning and Expression of the Type 1 and Type 2 Murine Receptors for Tumor Necrosis Factor.”Mol. Cell. Bio.11:3020-3026 (1991).
Gras et al., “BCMAp: An Integral Membrane Protein in the Golgi Apparatus of Human Mature B Lymphocytes.”Int. Immunology.7:1093-1106 (1995).
Green and Flavell., “TRANCE-RANK, A New Signal Pathway Involved in Lymphocyte Development and T Cell Activation.”J. Experimental Medicine. 189:1017-1020 (Apr. 1999).
Griffith et al., “Monocyte-mediated Tumoricidial Activity via the Tumor Necrosis Factor-related Cytokine, TRAIL”Journal of Experimental Medicine189:1343-1353 (1999).
Gruss and Dower, “Tumor Necrosis Factor Ligand Superfamily: Involvement in the Pathology of Malignant Lymphomas”Blood85:3378-3404 (1995).
Hahne et al., “Apr. A New Ligand of the Tumor Necrosis Factor Family, Stimulates Tumor Cell Growth.”Journal of Experimental Medicine188(6):1185-1190 (1998).
Hale et al., “Demonstration of In Vitro and In Vivo Efficacy of Two Biologically Active Human Soluble TNF Receptors Expressed inE. coli.”J. Cell. Biochem. (abstract only, suppl. 15F; P 424) pp. 113 (1991).
Hillier et al., “Generation and Analysis of 280,000 Human Expressed Sequence Tags”Genome Research6(9):807-828 (
Chuntharapai Anan
Kim Kyung Jin
Genentech Inc.
Kaufman Claire M.
Marschang Diane L.
Sidley Austin LLP
Spector Lorraine
LandOfFree
Human DR4 antibodies and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human DR4 antibodies and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human DR4 antibodies and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3855204